May 15, 2024

To all stakeholders,

Perseus Proteomics Inc.
Securities Code: 4882 Growth TSE
ir@ppmx.com

Notice on Booking of Non-operating Income, Non-operating Expenses, and Extraordinary Losses

Perseus Proteomics Inc. (The Company) announces that the non-operating income, non-operating expenses, and extraordinary losses were booked in the fiscal year ended March 31, 2024. The details are as follows:

1. Non-operating income

   The Company has booked foreign exchange gains of 16,924 thousand yen, and outsourcing service income of 4,136 thousand yen, as non-operating income respectively.

2. Non-operating expenses

   The Company has booked issuance cost of the 28th share acquisition rights of 5,528 thousand yen as non-operating expenses.

3. Extraordinary losses

   The Company has booked impairment loss of 153,887 thousand yen for its non-current assets in accordance with the Accounting Standard for Impairment of Fixed Assets and head office relocation expenses of 69,403 thousand yen as extraordinary losses, respectively.

4. Impact on financial results

   The above items have been fully reflected in the “Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2024” announced today.

END